MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
24.81
+1.82
+7.92%
Opening 13:30 12/19 EST
OPEN
23.04
PREV CLOSE
22.99
HIGH
25.02
LOW
23.00
VOLUME
506.60K
TURNOVER
--
52 WEEK HIGH
25.02
52 WEEK LOW
6.42
MARKET CAP
1.32B
P/E (TTM)
-13.1996
1D
5D
1M
3M
1Y
5Y
1D
Tyra Biosciences Chief Discovery Officer Daniel Bensen Reports Sale of Common Shares
Reuters · 2d ago
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 3d ago
Tyra Biosciences Price Target Raised to $37.00/Share From $30.00 by Wedbush
Dow Jones · 3d ago
Tyra Biosciences Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $37
Benzinga · 3d ago
TYRA BIOSCIENCES INC <TYRA.O>: WEDBUSH RAISES TARGET PRICE TO $37 FROM $30
Reuters · 3d ago
Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List
TipRanks · 3d ago
Assessing Tyra Biosciences (TYRA) Valuation Following Key Executive Hires to Support Advancing Clinical Pipeline
Simply Wall St · 4d ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.